tiprankstipranks
Advertisement
Advertisement
Voyager Therapeutics presents six-month toxicology data for VY1706
PremiumThe FlyVoyager Therapeutics presents six-month toxicology data for VY1706
1M ago
Voyager Therapeutics Expands Authorized Shares After Stockholder Vote
Premium
Company Announcements
Voyager Therapeutics Expands Authorized Shares After Stockholder Vote
2M ago
Voyager Therapeutics announces FDA clearance for VY1706 IND application
Premium
The Fly
Voyager Therapeutics announces FDA clearance for VY1706 IND application
3M ago
Voyager Therapeutics Warns of Broad Risk Exposure and Uncertain Outlook in Latest SEC Filings
PremiumCompany AnnouncementsVoyager Therapeutics Warns of Broad Risk Exposure and Uncertain Outlook in Latest SEC Filings
4M ago
Analyst Reaffirms Buy on Voyager Therapeutics as Strong Cash Runway and Advancing Neurology Pipeline Set Up Multiple 2026 Catalysts
Premium
Ratings
Analyst Reaffirms Buy on Voyager Therapeutics as Strong Cash Runway and Advancing Neurology Pipeline Set Up Multiple 2026 Catalysts
4M ago
Voyager Therapeutics reports Q1 EPS (47c), consensus (53c)
Premium
The Fly
Voyager Therapeutics reports Q1 EPS (47c), consensus (53c)
4M ago
Voyager Therapeutics: Early-Stage Tau Program Optionality Drives High-Risk, High-Upside Buy Rating
PremiumRatingsVoyager Therapeutics: Early-Stage Tau Program Optionality Drives High-Risk, High-Upside Buy Rating
5M ago
Voyager Therapeutics: Differentiated CNS Platform, Strategic Partnerships, and 2026 Data Catalysts Underpin Buy Rating
Premium
Ratings
Voyager Therapeutics: Differentiated CNS Platform, Strategic Partnerships, and 2026 Data Catalysts Underpin Buy Rating
5M ago
Voyager Therapeutics: Advancing Tau-Targeted Gene Therapy with Multiple Near-Term Catalysts and Attractive Risk-Reward
Premium
Ratings
Voyager Therapeutics: Advancing Tau-Targeted Gene Therapy with Multiple Near-Term Catalysts and Attractive Risk-Reward
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100